Risk evaluation of new-onset atrial fibrillation complicating ST-segment elevation myocardial infarction: a comparison between GRACE and CHA2DS2-VASc scores

Clinical Interventions in Aging, Jun 2018

Risk evaluation of new-onset atrial fibrillation complicating ST-segment elevation myocardial infarction: a comparison between GRACE and CHA2DS2-VASc scores Jiachen Luo,1 Liming Dai,1 Jianming Li,2 Jinlong Zhao,1 Zhiqiang Li,1 Xiaoming Qin,1 Hongqiang Li,1 Baoxin Liu,1 Yidong Wei1 1Department of Cardiology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China; 2Department of Cardiovascular Division, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN, USA Purpose: New-onset atrial fibrillation (NOAF) is a common finding in patients with myocardial infarction (MI), but few studies are available regarding the prediction model for its risk estimation. Although Global Registry of Acute Coronary Events (GRACE) risk score (RS) has been recognized as an effective tool for the risk evaluation of clinical outcomes in patients with MI, its usefulness in the prediction of post-MI NOAF remains unclear. In this study, we sought to validate the discrimination performance of GRACE RS in the prediction of post-MI NOAF and to make a comparison with that of the CHA2DS2-VASc score in patients with ST-segment elevation myocardial infarction (STEMI). Patients and methods: A total of 488 patients with STEMI who were admitted to our hospital between May 2015 and October 2016 without a history of atrial fibrillation were retrospectively evaluated in this study. GRACE and CHA2DS2-VASc scores were calculated for each patient. Patients were divided into low (GRACE RS≤125)-, intermediate (GRACE RS 126–154)-, and high (GRACE RS≥155)-risk groups. Receiver operating characteristic curve analyses were performed to evaluate the discrimination performance of both RSs. Model calibration was evaluated by using Hosmer–Lemeshow goodness-of-fit test (HLS). Results: Of the 488 eligible patients, 49 (10.0%) developed NOAF during hospitalization. In the overall cohort, the discrimination performance of GRACE RS (C-statistic: 0.76, 95% CI: 0.72–0.80) was significantly better than that of CHA2DS2-VASc score (C-statistic: 0.68, 95% CI: 0.64–0.72; comparison p=0.03). For subgroup analysis, GRACE RS tended to be better than the CHA2DS2-VASc score in all but the intermediate-risk group as evidenced by C-statistics of 0.60 and 0.65 for GRACE and CHA2DS2-VASc scores, respectively. Excellent calibration was achieved except for GRACE RS in females (HLS p=0.05). Conclusion: The diagnostic performance of GRACE RS is relatively high as well as better than that of the CHA2DS2-VASc score with respect to the prediction of post-MI NOAF. Keywords: myocardial infarction, atrial fibrillation, GRACE risk score, CHA2DS2-VASc score, risk prediction

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://www.dovepress.com/getfile.php?fileID=42479

Risk evaluation of new-onset atrial fibrillation complicating ST-segment elevation myocardial infarction: a comparison between GRACE and CHA2DS2-VASc scores

Clinical Interventions in Aging Risk evaluation of new-onset atrial fibrillation complicating sT-segment elevation myocardial infarction: a comparison between GRACE and ChA Ds -VAsc scores Jiachen luo 1 liming Dai 1 Jianming li 0 Jinlong Zhao 1 Zhiqiang li 1 Xiaoming Qin 1 hongqiang li 1 Baoxin liu 1 Yidong Wei 1 0 Department of Cardiovascular Division, Minneapolis Veterans Affairs Medical Center , Minneapolis, Mn , UsA 1 Department of Cardiology, s hanghai Tenth People's h ospital, Tongji University school of Medicine , Shanghai , People's Republic of China 8 1 0 2 - l u J - 3 1 n o 8 1 1 . 2 2 . 8 3 . 4 5 y b / m o c . s s e r PowerdbyTCPDF(ww.tcpdf.org) Clinical Interventions in Aging 2018:13 1099-1109 1099 © 2018 Luo et al. This work is published and licensed by Dove Medical Press Limited. The ful terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). - Purpose: New-onset atrial fibrillation (NOAF) is a common finding in patients with myocardial infarction (MI), but few studies are available regarding the prediction model for its risk estimation. Although Global Registry of Acute Coronary Events (GRACE) risk score (RS) has been recognized as an effective tool for the risk evaluation of clinical outcomes in patients with MI, its usefulness in the prediction of post-MI NOAF remains unclear. In this study, we sought to validate the discrimination performance of GRACE RS in the prediction of post-MI NOAF and to make a comparison with that of the CHA2DS2-VASc score in patients with ST-segment elevation myocardial infarction (STEMI). Patients and methods: A total of 488 patients with STEMI who were admitted to our hospital between May 2015 and October 2016 without a history of atrial fibrillation were retrospectively evaluated in this study. GRACE and CHA2DS2-VASc scores were calculated for each patient. Patients were divided into low (GRACE RS#125)-, intermediate (GRACE RS 126–154)-, and high (GRACE RS$155)-risk groups. Receiver operating characteristic curve analyses were performed to evaluate the discrimination performance of both RSs. Model calibration was evaluated by using Hosmer–Lemeshow goodness-of-fit test (HLS). Results: Of the 488 eligible patients, 49 (10.0%) developed NOAF during hospitalization. In the overall cohort, the discrimination performance of GRACE RS (C-statistic: 0.76, 95% CI: 0.72–0.80) was significantly better than that of CHA2DS2-VASc score (C-statistic: 0.68, 95% CI: 0.64–0.72; comparison p=0.03). For subgroup analysis, GRACE RS tended to be better than the CHA2DS2-VASc score in all but the intermediate-risk group as evidenced by C-statistics of 0.60 and 0.65 for GRACE and CHA2DS2-VASc scores, respectively. Excellent calibration was achieved except for GRACE RS in females (HLS p=0.05). Conclusion: The diagnostic performance of GRACE RS is relatively high as well as better than that of the CHA2DS2-VASc score with respect to the prediction of post-MI NOAF. Keywords: myocardial infarction, atrial fibrillation, GRACE risk score, CHA2DS2-VASc score, risk prediction Introduction New-onset atrial fibrillation (NOAF) is a common finding with a reported incidence ranging from 4% to 21% in patients who are diagnosed with myocardial infarction (MI) and free from previous atrial fibrillation (AF). The prognostic impact of post-MI NOAF has been extensively studied during the past decades.1–3 In a previous meta-analysis, Jabre et al showed that post-MI NOAF was significantly associated with mortality and suggested that NOAF should be perceived as an independent risk factor for clinical outcomes rather than simply a risk indicator reflecting the severity of MI.4 Although the strategies for pre-existing AF management in patients with MI have been suggested in current clinical guidelines,5 it is still unclear whether a specific treatment (eg, anticoagulation therapy) should also be applied to those with NOAF. On the other hand, 18 there is still no dedicated scoring system available for the risk l-20 estimation of NOAF in the setting of MI, which may limit the -Ju3 selection of patients with MI who are appropriate for clinical 1on trials of anticoagulation therapy, heart failure management, or 181 other novel therapies to improve outcomes after NOAF. ..22 The CHA2DS2-VASc score has been recognized as an .483 effective tool for the risk evaluation of ischemic stroke y5b in patients with AF.6 In addition, the clinical utility of /om CHA2DS2-VASc score in predicting AF per se has been .css validated in a recently published study.7 In contrast, when re applying CHA2DS2-VASc score in an ST-segment elevation .vdoepww l.syeonu subsequent NOAF, the discrimination was poor as evidenced myocardial infarction (STEMI) cohort for the prediction of /sw laon by a C-statistic of 0.68,8 thus indicating the need for further / : tthp rsep research to propose a scoring system that is more effective from roF than the CHA2DS2-VASc score regarding the risk estimation de of post-MI NOAF. ldao Global Registry of Acute Coronary Events (GRACE) risk now score (RS) is originally proposed for the risk evaluation of indg mortality in patients with acute coronary syndrome (ACS).9 gA Furthermore, it has now been validated as an important tool isnn for the risk stratification of prognosis in various clinical itno settings.10,11 Nevertheless, the diagnostic performance of trvee GRACE RS in the risk assessment of post-MI NOAF remains lIna to be investigated. Given the fact that the individual comiilcn ponents, such as age and heart failure, included in GRACE C RS have been considered as the main risk factors for AF,12,13 we sought to validate the discrimination performance of GRACE RS for the prediction of post-MI NOAF, and to make a comparison with CHA2DS2-VASc score, using data from a STEMI cohort. Patients and methods study population The electronic medical records of all patients with STEMI who were admitted to the coronary care unit of Shanghai Tenth People’s Hospital between May 2015 and October 2016 were reviewed. The diagnosis of STEMI was based on the criteria of the Third Universal Definition of Myocardial infarction.14 Patients were included if they were 18 years old or older and were admitted within 24 hours of submit your manuscript | www.dovepress.com Dovepress the onset of ischemic chest pain; those who had pre-existing AF based on medical records, presented with AF at entry, underwent emergent bypass surgery or had missing data of the individual components of GRACE and CHA2DS2-VASc scores were excluded. The investigational review committee of Shanghai Tenth People’s Hospital had approved the study protocol. Informed consent was not required by the Institutional Review Board for the observational nature of our study. study design The GRACE 2.0 ACS Risk Calculator (see: http://www. outcomes–umassmedorg/grace/files/GRACE_RiskModel_ Coefficients.pdf) was used in our study to calculate the GRACE RS in which eight prognostic factors were included: age, on-admission heart rate, systolic blood pressure (SBP) and Killip class or diuretic usage, baseline creatinine level or a history of chronic kidney dysfunction (CKD), ST-segment deviation, elevated troponin or other necrosis cardiac biomarkers, and on-admission cardiac arrest.15 Notably, based on our inclusion criteria, ST-segment deviation and elevated troponin were qualified as “true” for each patient. Each factor included in CHA2DS2-VASc score (congestive heart failure [CHF], hypertension, age [65–74 years], diabetes, vascular disease, and sex category [female]) was assigned 1 point, except the age $75 years and stroke/ transient ischemic attack, which were assigned 2 points, leading to a maximum score of 9 points. Definitions AF was defined as the absence of P waves with irregular RR intervals lasting for at least 30 seconds. NOAF was considered as patients with no history of AF who presented with sinus rhythm at entry and developed AF during the index hospitalization. Definitions of other baseline characteristics are presented in Table S1. statistical analysis The baseline data were compared using an independentsample t-test for normally distributed continuous variables, Wilcoxon rank-sum test for skewed variables, and χ2 or Fisher’s exact tests for categorical variables. Univariate logistic regression analysis was performed to identify which baseline characteristics were associated with post-MI NOAF. After including each of these confounding factors as evidenced by a p-value ,0.05 in the univariate analysis, multivariate logistic regression models were used to determine the independent risk factors for post-MI NOAF. Receiver 8 1 0 2 l u J 3 1 n o 8 1 1 . 2 2 . 8 3 . 4 5 y b / m o c . s s e r .vdoepw l.syeon w u /w la / :s on ttp rs h ep from roF d e d a o l n w o d g n i g A n i s n o it n e v tr e n lI a c ili n C operating characteristic curve analysis was performed to evaluate the discrimination performance of GRACE and CHA2DS2-VASc scores. We used the method described by Hanley and McNeil to compare the correlated C-statistic.16 Model calibration was evaluated according to the Hosmer– Lemeshow goodness-of-fit test (HLS). All patients were divided into three groups based on GRACE risk categories (low-risk #125, intermediate-risk 126–154, and highrisk $155), the associations between NOAF incidence and GRACE and CHA2DS2-VASc scores stratification were assessed using Spearman rank correlation test, respectively. We also explored the sex-based differences in both RSs when evaluating the risk of NOAF. A two-sided p,0.05 was considered statistically significant for all analyses. All these tests were performed using SPSS Statistics version 22.0 (IBM Corporation, Armonk, NY, USA). Results A total of 527 patients with STEMI were identified between May 2015 and October 2016. After applying the exclusion criteria, the final study cohort comprised a total of 488 patients with STEMI who did not have a history of AF (Figure 1). Baseline demographic and clinical characteristics of the patients are summarized in Table 1. The overall incidence of post-MI NOAF was 10.0% (n=49). Of the study population, the mean age was 65 years and 101 (21%) patients were women. Patients who suffered NOAF during hospitalization were older and more likely to be women compared with those not developing NOAF. A higher proportion of NOAF patients had a history of CKD and CHF as well as a higher level of initial Killip class in comparison with those not developing NOAF. GRACE and CHA2DS2-VASc scores were higher in NOAF patients compared with those in sinus rhythm. In addition, patients with 15 patients with missing data of risk scores 5 patients with AF history Initial cohort: 527 STEMI patients Final cohort: 488 STEMI patients 3 patients with emergent CABG 16 patients with on-admission AF NOAF had a higher brain natriuretic peptide level, a larger atrial diameter and a lower ejection fraction compared with those not developing NOAF. A higher proportion of NOAF patients were receiving diuretic or inotrope treatment during hospitalization compared with no NOAF subjects (Table 2). Baseline characteristics of included patients categorized by sex and GRACE RS stratification are shown in Tables S2 and S3, respectively. Association between NOAF incidence and grACe and ChA 2Ds 2-VAsc scores stratification Figure 2 illustrates the post-MI NOAF incidence increased in a graded manner across GRACE RS (range: 4.2%–22.9%) and CHA2DS2-VASc score stratification (range: 1.9%–13.0%). Furthermore, the association between NOAF incidence and GRACE RS stratification (r=0.24, p,0.01) tended to be more robust than that between NOAF incidence and CHA2DS2VASc score stratification (r=0.14, p,0.01). The discrimination performance of grACe and ChA 2Ds 2-VAsc scores The GRACE RS showed a high discrimination performance for the prediction of post-MI NOAF as evidenced by a C-statistic of 0.76 (95% CI: 0.72–0.80) in the overall population, which was better than that of the CHA2DS2-VASc score (C-statistic: 0.68, 95% CI: 0.64–0.72; comparison p=0.03; Figure 3A). In subgroup analyses, we illustrated the usefulness of GRACE RS in both men and women appeared to be better than that of the CHA2DS2-VASc score, although the superiority had not reached significance (Figure 3B and C). Of note, only a suboptimal calibration (HLS p=0.05) of GRACE RS was achieved in females. In addition, the diagnostic performance of GRACE RS tended to be better than that of the CHA2DS2-VASc score in all risk categories except for the intermediate-risk group, in which GRACE RS (C-statistic: 0.60, 95% CI: 0.51–0.69) was inferior to CHA2DS2-VASc score (C-statistic: 0.65, 95% CI: 0.56–0.73). Both RSs achieved excellent calibration in all risk categories (Figure 3D–F). The sensitivity and specificity of GRACE and CHA2DS2-VASc scores for the prediction of post-MI NOAF are presented in Table S4. Independent risk factors for post-MI nOAF As shown in Table 3, advanced age was demonstrated as the only independent factor for post-MI NOAF in the overall p-value population (OR: 1.63, 95% CI: 1.17–2.26; p,0.01) based on the multivariable logistic regression model. Discussion Main findings The main findings were as follows. First, the incidence of post-MI NOAF increased in a stepwise manner with the increase of GRACE and CHA DS2-VASc score risk strati2 fication. Second, the diagnostic performance of GRACE RS for the prediction of post-MI NOAF during hospitalization was relatively high as well as better than that of the CHA DS2-VASc score. Notably, GRACE RS had a better 2 discriminative value than the CHA DS2-VASc score in all 2 subgroups except in the intermediate-risk group. Third, caution should be noted when evaluating the risk of post-MI NOAF in females with the use of GRACE RS given its suboptimal calibration. The detrimental impact of post-MI NOAF has been extensively studied.1,3,4 In line with previous studies, we also showed that NOAF complicating STEMI was associated with a nearly 3.7-fold increased risk of in-hospital death (OR: 3.72, 95% CI: 1.48–9.36). NOAF may lead to adverse outcomes 1102 in patients with MI through several pathways, such as loss of atrioventricular synchrony and atrial constriction, and rapid heart rate, leading to the deterioration of heart failure; intra-cardiac thrombus formation contributing to ischemic stroke or systemic embolism.3,4,17 However, few studies with respect to the establishment of prediction models for the risk evaluation of post-MI NOAF have been conducted.8 While the CHA2DS2-VASc score is recommended for the risk evaluation of ischemic stroke in patients with AF,6 several previous studies7,8 had been performed to explore its clinical utility in the prediction of AF per se. In a population-based study, the usefulness of both CHADS2 and CHA DS2-VASc 2 scores in NOAF prediction was investigated in participants with no history of AF, the results of which (C-statistics: 0.73 and 0.74 for CHADS2 and CHA DS2-VASc scores, respec2 tively) seemed to advocate its utility.7 Of note, their results may not be extended to patients with MI. Indeed, in an ACS cohort, Mitchell and colleagues showed that both CHADS2 and CHA DS2-VASc scores were ineffective for the predic2 tion of incident AF.18 Similarly, in our study, the diagnostic performance of CHA DS2-VASc score was relatively poor 2 as evidenced by a C-statistic of 0.68. 8 1 0 2 l u J 3 1 n o 8 1 1 . 2 2 . 8 3 . 4 5 y b / m o c . s s e r .vdoepw l.syeon Total (n=488) Sinus rhythm (n=439) NOAF (n=49) p-value Usefulness of grACe rs in the prediction of post-MI nOAF GRACE RS, an important risk evaluation model originally designed for the prediction of 6-month mortality in patients with ACS, has also been demonstrated in various clinical settings with excellent discrimination performance.9 However, until now, few data were available with respect to the usefulness of GRACE RS in AF prediction. In the present study, GRACE RS was shown to be a useful tool for the prediction of post-MI NOAF (C-statistic: 0.76) and was superior to the CHA DS2-VASc score. To the best of our 2 knowledge, this is the first study regarding the usefulness of GRACE RS in post-MI NOAF prediction. The usefulness of GRACE RS for NOAF prediction in patients with STEMI is not surprising. First, several components included in GRACE RS have been demonstrated as the main risk factors for AF. For example, the Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary submit your manuscript | www.dovepress.com Dovepress 1103 8 1 0 2 l u J 3 1 n o 8 1 1 . 2 2 . 8 3 . 4 5 y b / m o c . s s e r .vdoepw l.syeon 25.0% 20.0% e c en15.0% d i c n i FA10.0% O N 5.0% 0.0% CHA2DS2-VASc score GRACE risk score Low-risk 1.9% 4.2% Intermediate-risk 5.9% 15.9% High-risk 13.0% 22.9% w u /:/sw lona Arteries (GUSTO-I) investigators had validated that age, ttph rsep higher Killip class and heart rate, and lower SBP were from roF independent predictors of NOAF complicating STEMI.3 ed Second, NOAF has often been perceived as a risk indicator laod reflecting the deterioration of heart failure, a major risk faconw tor for death in patients with MI who generally had a higher idng GRACE RS compared with those not developing heart failure gA or NOAF.4 Indeed, we demonstrated a stepwise increased isnn association between GRACE risk stratification and NOAF iton incidence (Figure 2). trvee In our subgroup analysis based on GRACE RS stratificalIna tion, acceptable diagnostic performance was only observed ilicn in the low-risk group. However, this finding should not cast C doubt on the usefulness of GRACE RS in intermediate- and high-risk groups because the limited numbers of patients and events might preclude the achievement of statistical significance (Table S3). sex-related differences in grACe and ChA 2Ds 2-VAsc scores for nOAF prediction The prognostic impact of sex-related differences in patients with ACS has been studied.19 In general, women with ACS tend to present with more atypical symptoms and have higher risk profiles and comorbidities.20 In line with previous studies, we also showed that women were at higher risk for developing post-MI NOAF in comparison with men. There1104 submit your manuscript | www.dovepress.com Dovepress fore, it is necessary to explore the usefulness of GRACE and CHA2DS2-VASc scores across sex categories. Of note, in our study, GRACE RS only achieved a suboptimal calibration (HLS p=0.05) and discrimination (C-statistic: 0.69; 95% CI: 0.59–0.78) in females, which was different from that in males (C-statistic: 0.74; 95% CI: 0.70–0.78; HLS p=0.37). However, this was not hard to imagine because female sex is not a component factor included in GRACE RS. As a result, caution is required when GRACE RS is used to evaluate the risk stratification of post-MI NOAF in females. Several limitations of this study should be noted. First, this was a single-center retrospective study with a relatively small sample size; therefore, the results should be considered as hypothesis generating and warranting validation by multicenter studies. Second, although we had excluded patients with a history of AF based on medical records, there might be subjects who had asymptomatic AF events before the index STEMI being misclassified as NOAF, given the high prevalence of asymptomatic AF.21 In fact, this is an inherent limitation almost to all studies regarding NOAF identification.7,17 Third, we sought to evaluate the usefulness of GRACE RS in the prediction of post-MI NOAF during hospitalization, its value in recurrent AF prediction was not assessed due to the lack of follow-up data. We also failed to demonstrate the detrimental impact of recurrent AF on clinical outcomes, which should be validated in the future. 8 1 0 2 l u J 3 1 n o 8 1 1 . 2 2 . 8 3 . 4 5 y b / m o c . s s e r d e d a o l n w o d g n i g A n i s n o it n e v r e t n lI a c i n li C from roF Conclusion In patients with STEMI but no history of AF, the diagnostic performance of GRACE RS in the prediction of post-MI NOAF is better than that of the CHA2DS2-VASc score. With the use of GRACE RS, it will be convenient to identify patients with MI who are at high risk of subsequent NOAF and may benefit from enhanced electronic monitoring. Further prospective studies are warranted to validate our findings. Acknowledgments This work was supported by the National Natural Science Foundation of China (grant numbers 81270193 and 30800466). submit your manuscript | www.dovepress.com Dovepress 1105 8 1 0 2 l u J 3 1 n o 8 1 1 . 2 2 . 8 3 . 4 5 y b / m o c . s s e r .vdoepw l.syeon Author contributions This manuscript was drafted by JC Luo. YD Wei and JC Luo contributed to the conception and design of the article. LM Dai, HQ Li, and ZQ Li contributed to the acquisition and analysis of data. JM Li, BX Liu, JL Zhao, and XM Qin contributed to the critical revision of the paper. All Authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work. Disclosure The authors report no conflicts of interest in this work. submit your manuscript | www.dovepress.com Dovepress 8 1 0 2 l u J 3 1 n o 8 1 1 . 2 2 . 8 3 . 4 5 y b / m o c . s s e r .vdoepw l.syeon Supplementary materials Notes: aOn-admission Killip class .I. Data presented as n (%) or mean ± sD. Abbreviations: CHF, chronic heart failure; CKD, chronic kidney dysfunction; GRACE, Global Registry of Acute Coronary Events; HF, heart failure; HR, heart rate; MI, myocardial infarction; NOAF, new-onset atrial fibrillation; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; SR, sinus rhythm; TIA, transient ischemic attack. submit your manuscript | www.dovepress.com Dovepress 1107 8 1 0 2 l u J 3 1 n o 8 1 1 . 2 2 . 8 3 . 4 5 y b / m o c . s s e r .vdoepw l.syeon Notes: aOn-admission Killip class .I. Data presented as n (%) or mean ± sD. Abbreviations: CHF, chronic heart failure; CKD, chronic kidney dysfunction; GRACE, Global Registry of Acute Coronary Events; HF, heart failure; HR, heart rate; MI, myocardial infarction; NOAF, new-onset atrial fibrillation; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; SR, sinus rhythm; TIA, transient ischemic attack. Predictive model (optimal cut-off value) w u /w la / :s on ttp rs h ep from roF d e d a o l n w o d g n i g A n i s n o it n e v r e t n lI a c i n li C Overall cohort grACe risk score ( .118) ChA 2Ds2-VAsc score (.2) sex category Male grACe risk score ( .116) ChA 2Ds2-VAsc score (.2) Female grACe risk score ( .140) ChA 2Ds2-VAsc score (.3) GRACE risk score stratification low-risk ( #125) grACe risk score ( .112) ChA 2Ds2-VAsc score (.0) Intermediate-risk (126 to 154) grACe risk score ( .136) ChA 2Ds2-VAsc score (.3) high-risk ( $155) grACe risk score ( .170) ChA 2Ds2-VAsc score (#3) Abbreviation: GRACE, Global Registry of Acute Coronary Events. Publish your work in this journal Clinical Interventions in Aging is an international, peer-reviewed journal focusing on evidence-based reports on the value or lack thereof of treatments intended to prevent or delay the onset of maladaptive correlates of aging in human beings. This journal is indexed on PubMed Central, MedLine, CAS, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress. com/testimonials.php to read real quotes from published authors. 1. Daskalopoulou S , Khan N , Quinn R , et al. The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy . Can J Cardiol . 2012 ; 28 ( 3 ): 270 - 287 . 2. American Diabetes Association. Diagnosis and classification of diabetes mellitus . Diabetes Care . 2011 ; 34 ( Suppl 1 ): S62 - S69 . 3. Anderson T , Grégoire J , Hegele R , et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult . Can J Cardiol . 2013 ; 29 ( 2 ): 151 - 167 .


This is a preview of a remote PDF: https://www.dovepress.com/getfile.php?fileID=42479

Jiachen Luo, Liming Dai, Jianming Li, Jinlong Zhao, Zhiqiang Li, Xiaoming Qin, Hongqiang Li, Baoxin Liu, Yidong Wei. Risk evaluation of new-onset atrial fibrillation complicating ST-segment elevation myocardial infarction: a comparison between GRACE and CHA2DS2-VASc scores, Clinical Interventions in Aging, 2018, 1099-1109, DOI: 10.2147/CIA.S166100